A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

Phase 3

Active, not recruiting

• Conditions: Early Alzheimer's Disease
• Interventions: Drug: Semagludtide; Drug: Placebo (semaglutide)

• Registration Number: NCT04777396
• Lead Sponsor: Novo Nordisk A/S

Brief Summary

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.

Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance.

The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits participants will have blood samples taken.

Participants must have a study partner, who is willing to take part in the study.

Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period.

A cerebrospinal fluid (CSF) sub-study will be performed as a part of the study. The sub-study will be performed on a selection of sites based on their experience with CSF sampling and willingness to participate in this sub-study. The endpoints related to this sub-study are exploratory only.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-02-26
• Study First Submitted QC: 2021-02-26
• Study First Posted: 2021-03-02
• Study Start: 2021-05-18
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-27
• Last Update Posted: 2025-04-29
• Primary Completion: 2025-09-19
• Study Completion: 2026-10-23

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 1840

Inclusion Criteria

• Male or female, aged 55-85 years (both inclusive) at the time of signing informed consent.
• MCI (mild cognitive impairment) or mild dementia of the Alzheimer's type according to the NIA-AA (National Institute of Aging-Alzheimer's Association) 2018 criteria.
• CDR (Clinical Dementia Rating) global score of 0.5 and CDR of 0.5 or more in at least one of the three instrumental activities of daily living categories (personal care, home & hobbies, community affairs) Or CDR global score of 1.0
• RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) delayed memory index score of below or equal to 85
• MMSE (Mini-Mental State Examination) greater than or equal to 22
• Amyloid positivity established with either amyloid PET (positron emission tomography), CSF (cerebrospinal fluid) Aβ1-42 or CSF Aβ1-42/Aβ1-40 .
• If receiving an approved Alzheimer's disease treatment (such as acetylcholinesterase inhibitors, memantine or aducanumab) the dose must have been stable for at least 3 months prior to screening and should not be changed during the trial unless medically necessary.

Exclusion Criteria

• Brain MRI (or CT) scan suggestive of clinically significant structural CNS disease confirmed by central read (e.g. cerebral large-vessel disease [large vessel (cortical) infarcts greater than 10 mm in diameter], prior macro-haemorrhage [greater than 1 cm^3], cerebral vascular malformations, cortical hemosiderosis, intracranial aneurism(s), intracranial tumours, changes suggestive of normal pressure hydrocephalus).
• Brain MRI (magnetic resonance imaging) (or CT) scan suggestive of significant small vessel pathology confirmed by central read and defined as greater than1 lacunar infarct and/or ARWMC (age-related white matter changes) greater than 2, (WM (white matter) greater than 20 mm) in the deep white matter and periventricular regions.
• Brain MRI (or CT) scan suggestive of strategic infarcts defined as bilateral thalamic lacunar infarcts and singular paramedian thalamic infarcts confirmed by central read.
• Evidence of a relevant neurological disorder other than MCI or mild dementia of the Alzheimer's type at screening, including but not limited to Parkinson's disease, Lewy body disease, frontotemporal dementia of any type, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, systemic lupus erythematosus, progressive supranuclear palsy, neurosyphilis, HIV (human immunodeficiency virus), learning disability, intellectual disability, hypoxic cerebral damage, or significant head trauma with loss of consciousness that led to persistent cognitive deficits
• Evidence of a clinically relevant or unstable psychiatric disorder, based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria, including schizophrenia or other psychotic disorder, or bipolar disorder. A subject with a history of major depression who has not had an episode in the last 24 months before the day of screening and is considered in remission or whose depression is controlled with treatment can be included in the trial per investigator's judgement.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Oral Semaglutide	Semagludtide	Participants are given oral semaglutide once daily
Placebo (semagludtide)	Placebo (semaglutide)	Participants are given oral placebo once daily

Primary Outcome Measures

Name	Time	Method
Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score	From baseline (week 0) to week 104	Score on scale (0 to 18); Measures the impact of cognitive decline on daily function using the following six domains commonly affected in Alzheimer's disease: * Cognitive domains: memory, orientation, and judgement and problem solving; * Function domains: community affairs, home and hobbies, and personal care Based on clinical information obtained from the subject and informant, an individual box score ranging from 0 to 3 is determined that represents "none" to "severe" impairment for each of the six domains.; The CDR-Sum of Boxes (CDR-SB) score will be derived by adding the individual scores of the six domains at a given time point. The total CDR-SB score ranges from 0 to 18 with higher scores representing greater impairment.

Secondary Outcome Measures

Name	Time	Method
Extension Phase: Number of treatment emergent adverse events (TEAEs)	From baseline (week 0) up to week 156	Number of events
Main Phase: Change in the 24-item Alzheimer's Disease Cooperative Study Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-ADL-MCI) score	From baseline (week 0) to week 104	Score on scale (0 to 53) An interview-based assessment of information provided by the study partner (informant). The total scores based on 18 items on the scale range from 0 to 53 with lower scores representing greater impairment.
Extension Phase:Change in the ADCS-ADL-MCI (Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory-Mild Cognitive Impairment ) score	From baseline (week 0) to week 156	Score on scale (0 to 53) An interview-based assessment of information provided by the study partner (informant). The total scores based on 18 items on the scale range from 0 to 53 with lower scores representing greater impairment.
Main Phase: Time to progression to Clinical Dementia Rating (CDR) global score greater than or equal to (≥) 1.0 among patients with CDR global score equal to (=) 0.5 at baseline	From baseline (week 0) up to week 156	Week(s)
Extension Phase: Time to progression to Clinical Dementia Rating (CDR) global score greater than or equal to (≥) 1.0 among patients with CDR global score equal to (=) 0.5 at baseline	From baseline (week 0) to week 156	Week(s)
Main Phase: Change in the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog-13) score	From baseline (week 0) to week 104	Score on scale (0 to 85) ADAS-Cog-13 measures the severity of cognitive impairment in various domains including memory, language, orientation, praxis and executive function. The ADAS-Cog-13 is composed of tasks in the original 11-item ADAS-Cog as well as delayed word recall and number cancellation items. The total scores on the scale range from 0 to 85 with higher scores representing greater impairment.
Extension Phase: Change in the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog-13) score	From baseline (week 0) to week 156	Score on scale (0 to 85) ADAS-Cog-13 measures the severity of cognitive impairment in various domains including memory, language, orientation, praxis and executive function. The ADAS-Cog-13 is composed of tasks in the original 11-item ADAS-Cog as well as delayed word recall and number cancellation items. The total scores on the scale range from 0 to 85 with higher scores representing greater impairment.
Main Phase: Change in the Montreal Cognitive Assessment (MoCA) score	From baseline (week 0) to week 104	Score on scale (0 to 30) The MoCA is a brief assessment of cognitive abilities including orientation, short-term memory, clock-drawing test, executive function, language abilities, animal naming, attention and abstrac-tion. The assessment includes 8 domains of cognitive function with total scores ranging from 0 to 30 and lower scores indicating greater impairment.
Extension Phase: Change in the Montreal Cognitive Assessment (MoCA) score	From baseline (week 0) to week 156	Score on scale (0 to 30) The MoCA is a brief assessment of cognitive abilities including orientation, short-term memory, clock-drawing test, executive function, language abilities, animal naming, attention and abstrac-tion. The assessment includes 8 domains of cognitive function with total scores ranging from 0 to 30 and lower scores indicating greater impairment.
Main Phase: Change in the Alzheimer's Disease Composite Score (ADCOMS)	From baseline (week 0) to week 104	Score on scale (0 to 1.97) The ADCOMS is a composite clinical outcome comprising 4 items from the ADAS-Cog-13, 2 items from the MMSE and all 6 items from the CDR-SB.32 The total scores on the scale range from 0 to 1.97 with higher scores indicating greater impairment.
Extension Phase: Change in the Alzheimer's Disease Composite Score (ADCOMS)	From baseline (week 0) to week 156	Score on scale (0 to 1.97) The ADCOMS is a composite clinical outcome comprising 4 items from the ADAS-Cog-13, 2 items from the MMSE and all 6 items from the CDR-SB.32 The total scores on the scale range from 0 to 1.97 with higher scores indicating greater impairment.
Main Phase: Change in the Mini-Mental State Examination (MMSE) score	From baseline (week 0) to week 104	Score on scale (0 to 30) The MMSE measures orientation, attention, memory, language and visuo-spatial function. The total scores on the scale range from 0 to 30 with lower scores indicating greater impairment.
Extension Phase: Change in the Mini-Mental State Examination (MMSE) score	From baseline (week 0) to week 156	Score on scale (0 to 30) The MMSE measures orientation, attention, memory, language and visuo-spatial function. The total scores on the scale range from 0 to 30 with lower scores indicating greater impairment.
Main Phase: Time to progression in disease stage based on global CDR score	From baseline (week 0) up to week 156	Week(s)
Extension Phase: Time to progression in disease stage based on global CDR score	From baseline (week 0) up to week 156	Week(s)
Main Phase: Change in the composite Z-score based on the three outcome measures CDR-SB, ADCS-ADL-MCI, and ADAS-Cog-13	From baseline (week 0) to week 104	Score
Extension Phase: Change in the composite Z-score based on the three outcome measures CDR-SB, ADCS-ADL-MCI, and ADAS-Cog-13	From baseline (week 0) to week 156	Score
Main Phase: Change in the 10-item Neuropsychiatric Inventory (NPI) score	From baseline (week 0) to week 104	Score on scale (0 to 120) The 10-item scale assesses symptoms including delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability and aberrant motor activity. For each domain the frequency (4-point scale) and severity (3-point scale) of symptoms is reported. The score for each domain is calculated by multiplying the frequency and severity score. The total 10-item NPI score is 0 to 120 with higher scores indicating a greater symptomatology.
Extension Phase: Change in the 10-item Neuropsychiatric Inventory (NPI) score	From baseline (week 0) to week 156	Score on scale (0 to 120) The 10-item scale assesses symptoms including delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability and aberrant motor activity. For each domain the frequency (4-point scale) and severity (3-point scale) of symptoms is reported. The score for each domain is calculated by multiplying the frequency and severity score. The total 10-item NPI score is 0 to 120 with higher scores indicating a greater symptomatology.
Main Phase: Change in high sensitivity C-reactive protein level	From baseline (week 0) to week 104	Ratio to baseline
Extension Phase: Change in high sensitivity C-reactive protein level	From baseline (week 0) to week 156	Ratio to baseline
Main Phase: Number of treatment emergent adverse events (TEAEs)	From baseline (week 0) up to week 156	Number of events
Main Phase: Time to first occurrence of major adverse cardiovascular event (MACE) comprising non-fatal myocardial infarction, non-fatal stroke and all-cause death	From baseline (week 0) to week 104	Week(s)
Extension Phase: Time to first occurrence of major adverse cardiovascular event (MACE) comprising non-fatal myocardial infarction, non-fatal stroke and all-cause death	From baseline (week 0) to week 156	Week(s)
Main Phase: Time to first occurrence of stroke	From baseline (week 0) to week 104	Week(s
Extension Phase: Time to first occurrence of stroke	From baseline (week 0) to week 156	Week(s
Main Phase: Change in the EQ-5D-5L (proxy version) index score	From baseline (week 0) to week 104	Score The EQ-5D-5L descriptive system comprises mobility, self-care, usual activities, pain/discomfort and anxiety/depression with five response levels each (no problems, slight problems, moderate problems, severe problems, unable to /extreme problems). The EQ-5D-5L proxy version 1 (the study partner is asked to rate how he/she \[the proxy\] would rate the subject´s health) will be used in this trial.
Extension Phase: Change in the EQ-5D-5L (proxy version) index score	From baseline (week 0) to week 156	Score The EQ-5D-5L descriptive system comprises mobility, self-care, usual activities, pain/discomfort and anxiety/depression with five response levels each (no problems, slight problems, moderate problems, severe problems, unable to /extreme problems). The EQ-5D-5L proxy version 1 (the study partner is asked to rate how he/she \[the proxy\] would rate the subject´s health) will be used in this trial.
Extension phase: Change in the CDR-SB score	From baseline (week 0) to week 156	Score on scale (0 to 18); Measures the impact of cognitive decline on daily function using the following six domains commonly affected in Alzheimer's disease: * Cognitive domains: memory, orientation, and judgement and problem solving; * Function domains: community affairs, home and hobbies, and personal care Based on clinical information obtained from the subject and informant, an individual box score ranging from 0 to 3 is determined that represents "none" to "severe" impairment for each of the six domains.; The CDR-Sum of Boxes (CDR-SB) score will be derived by adding the individual scores of the six domains at a given time point. The total CDR-SB score ranges from 0 to 18 with higher scores representing greater impairment.

Trial Locations

Locations (342)

FLENI; 🇦🇷 Caba, Argentina

Instituto Privado Kremer; 🇦🇷 Córdoba, Argentina

Fundación Scherbovsky; 🇦🇷 Mendoza, Argentina

Memory Program; 🇨🇦 Toronto, Ontario, Canada

Ospedale Santa Maria della Misericordia; 🇮🇹 Perugia, Italy

Pol. Uni. Campus Biomedico UOC Neurologia; 🇮🇹 Roma, Italy

Centricity Research LMC; 🇨🇦 Toronto, Ontario, Canada

Sunnybrook Health Sciences Centre; 🇨🇦 Toronto, Ontario, Canada

University Health Network - Toronto Western Hospital; 🇨🇦 Toronto, Ontario, Canada

University Health Network; 🇨🇦 Toronto, Ontario, Canada

Rigshospitalet - afsnit 8015; 🇩🇰 København Ø, Denmark

Sjællands Universitetshospital_Roskilde; 🇩🇰 Roskilde, Denmark

CRST Helsinki; 🇫🇮 Helsinki, Finland

Aivotutkimusyksikkö; 🇫🇮 Kuopio, Finland

CRST Turku; 🇫🇮 Turku, Finland

University General Hospital of Athens "Attiko"; 🇬🇷 Chaidari, Athens, Greece

Iatriko Athinon (Athens Medical Center),Memory Disorders Cli; 🇬🇷 Marousi, Greece

AHEPA General University Hospital; 🇬🇷 Thessaloniki, Greece

EUROMEDICA General Clinic of Thessaloniki,Neurology Dpt; 🇬🇷 Thessaloniki, Greece

Semmelweis Egyetem ÁOK; 🇭🇺 Budapest, Hungary

Somogy Megyei Kaposi Mór Oktató Kórház; 🇭🇺 Kaposvár, Hungary

Psychotech Kft.; 🇭🇺 Pécs, Hungary

Belvárosi Egészségház Kft.; 🇭🇺 Zalaegerszeg, Hungary

Mercy Hospital Cork; 🇮🇪 Cork, Ireland

St Vincent's University Hospital; 🇮🇪 Dublin, Ireland

Mercer's Institute for Successful Aging; 🇮🇪 Dublin, Ireland

Tallaght University Hospital; 🇮🇪 Dublin, Ireland

The Stroke and Cognition Institute Rambam Medical Center; 🇮🇱 Haifa, Israel

Cognitive Neurology Clinic, Rabin Campus, Beilinson Hospital; 🇮🇱 Petach Tikva, Israel

Cognitive Neurology Sourasky Medical Center; 🇮🇱 Tel Aviv, Israel

Chaim Sheba Medical Center, Heart Screening Clinic, 1st floor, Room 317; 🇮🇱 Tel Hashomer, Ramat Gan, Israel

AOU Ospedali Riuniti S.O.D; 🇮🇹 Ancona, Italy

Azienda Ospedaliera Spedali Civili di Brescia; 🇮🇹 Brescia, Italy

Università degli studi Gabriele D'Annunzio Chieti-Pescara; 🇮🇹 Chieti, Italy

Fondazione IRCSS Ca' Granda Ospedale Maggiore Policlinico; 🇮🇹 Milano, Italy

IRCCS Ospedale San Raffaele Milano; 🇮🇹 Milano, Italy

ASST Monza e Brianza Ospedale San Gerardo; 🇮🇹 Monza, Italy

Policlinico Tor Vergata; 🇮🇹 Roma, Italy

Policlinico Universitario A.Gemelli Servizio Neuropsicologia; 🇮🇹 Roma, Italy

Fondazione Santa Lucia IRCCS; 🇮🇹 Roma, Italy

Iwaki Clinic_Psychosomatic medicine; 🇯🇵 Anan, Tokushima, Japan

Yachiyo Hospital; 🇯🇵 Anjo-shi, Aichi, Japan

Abe Clinic; 🇯🇵 Arakawa-ku,Tokyo, Japan

Memory Clinic Ochanomizu; 🇯🇵 Bunkyo-ku, Tokyo, Japan

Tokyo Medical And Dental University Hospital; 🇯🇵 Bunkyo-ku,Tokyo, Japan

Kashiwado Hospital; 🇯🇵 Chib-shi, Chiba, Japan

Enomoto Internal Medicine Clinic; 🇯🇵 Chofu-shi,Tokyo, Japan

Shinozuka Hospital; 🇯🇵 Fujioka-Shi, Gunma, Japan

P-one Clinic; 🇯🇵 Hachioji-shi, Tokyo, Japan

National Hospital Organization Tenryu Hospital; 🇯🇵 Hamamatsu-shi, Shizuoka, Japan

Hyogo Brain and Heart Center; 🇯🇵 Himeji-city, Hyogo, Japan

Tsukazaki Hospital; 🇯🇵 Himeji-shi, Hyogo, Japan

Himeji Central Hospital Clinic; 🇯🇵 Himeji-shi, Hyogo, Japan

Hatsuta Neurology Clinic; 🇯🇵 Hirakata-Shi,Osaka, Japan

Imon Yukari Neurology Clinic; 🇯🇵 Hiroshima-shi, Hiroshima, Japan

Hikaru-kai Medical Corporation Hiroshima Neurology Clinic; 🇯🇵 Hiroshima-shi, Hiroshima, Japan

Nagamitsu Clinic; 🇯🇵 Hofu-shi, Yamaguchi, Japan

Ina Central Hospital; 🇯🇵 Ina-shi, Nagano, Japan

Kawasaki Saiwai Clinic_Internal Medicine; 🇯🇵 Kanagawa, Japan

Kishiro Mental Clinic; 🇯🇵 Kawasaki-shi , Kanagawa, Japan

Koukan Clinic; 🇯🇵 Kawasaki-shi, Kanagawa, Japan

Teikyo University Hospital, Mizonokuchi_Kawasaki-shi, Kanagawa; 🇯🇵 Kawasaki-shi, Kanagawa, Japan

Kobe University Hospital_Kobe-shi, Hyogo; 🇯🇵 Kobe-shi, Hyogo, Japan

National Center of Neurology and Psychiatry; 🇯🇵 Kodaira-shi, Tokyo, Japan

Southern Tohoku Medical Clinic; 🇯🇵 Koriyama-shi, Fukushima, Japan

Jichiidai Station Brain Clinic; 🇯🇵 Shimotsuke-shi, Tochigi, Japan

Katayama Medical Clinic; 🇯🇵 Kurashiki-shi, Okayama, Japan

Nozomi Memory Clinic; 🇯🇵 Mitaka-shi,Tokyo, Japan

Kikukawa clinic; 🇯🇵 Nerima-ku, Tokyo, Japan

General Rehabilitation Center · Midori Hospital; 🇯🇵 Niigata-shi, Niigata, Japan

National Center for Geriatrics and Gerontology; 🇯🇵 Obu-shi, Aichi, Japan

Oslo universitetssykehus HF, Ullevål; 🇳🇴 Oslo, Norway

Master Centre - Dummy; 🇳🇴 Oslo, Norway

Centrum Zdrowia Psychicznego Biomed; 🇵🇱 Kielce, Poland

Centrum Neurologii Klinicznej; 🇵🇱 Kraków, Poland

Szpital Uniwersytecki w Krakowie od. Neurologii; 🇵🇱 Kraków, Poland

Nzoz Neuromed; 🇵🇱 Lublin, Poland

NZOZ NEURO - KARD Ilkowski i Partnerzy Sp. Part. Lekarzy; 🇵🇱 Poznan, Poland

Osrodek Alzheimerowski Sp. z o.o.; 🇵🇱 Scinawa, Poland

Centrum Medyczne SENIOR; 🇵🇱 Sopot, Poland

Centrum Medyczne Neuro Protect; 🇵🇱 Warszawa, Poland

NZOZ Wrocławskie Centrum Alzheimerowskie; 🇵🇱 Wroclaw, Poland

Unidade Local De Saude De Matosinhos E.P.E.; 🇵🇹 Senhora Da Hora, Matosinhos, Matosinhos, Portugal

Hospital de Braga; 🇵🇹 Braga, Portugal

Unidade Local de Saúde de Coimbra, E.P.E.; 🇵🇹 Coimbra, Portugal

Unidade Local de Saude do Alto Ave, E.P.E.; 🇵🇹 Guimarães, Portugal

Bugát Pál Kórház; 🇭🇺 Gyöngyös, Hungary

UKC Maribor - neurology; 🇸🇮 Maribor, Slovenia

Hôpital Roger Salengro; 🇫🇷 Lille CEDEX, France

Saino Clinic; 🇯🇵 Tokorozawa-shi,Saitama, Japan

Itsuki Hospital; 🇯🇵 Tokushima-shi, Tokushima, Japan

Alzclinic Tokyo; 🇯🇵 Tokyo, Japan

Tokyo Center Clinic; 🇯🇵 Tokyo, Japan

Centrum Medyczne Neuromed; 🇵🇱 Bydgoszcz, Poland

Banner Alzheimer's Institute; 🇺🇸 Phoenix, Arizona, United States

Imaging Endpoints; 🇺🇸 Scottsdale, Arizona, United States

Recherches Neuro-Hippocampe Inc; 🇨🇦 Ottowa, Ontario, Canada

Univ. Klinik für Neurologie; 🇦🇹 Salzburg, Austria

Petz Aladar Megyei Oktato Korhaz; 🇭🇺 Gyor, Hungary

UZA - UZ Antwerpen - Department of Neurology; 🇧🇪 Edegem, Belgium

Banner Sun Health Research Institute; 🇺🇸 Sun City, Arizona, United States

Advanced Research Center, Inc.; 🇺🇸 Anaheim, California, United States

Fullerton Neurology and Headache Center; 🇺🇸 Fullerton, California, United States

Pacific Research Network; 🇺🇸 Lemon Grove, California, United States

Torrance Clin Res Inst, Inc.; 🇺🇸 Lomita, California, United States

ASCLEPES Research Centers,; 🇺🇸 Long Beach, California, United States

UCLA_Los Angeles; 🇺🇸 Los Angeles, California, United States

Well Care Medical Center; 🇺🇸 Panorama City, California, United States

Cedars-Sinai Medical Center; 🇺🇸 Pasadena, California, United States

Sharp Neurocog Res Ctr; 🇺🇸 San Diego, California, United States

Syrentis Clinical Research; 🇺🇸 Santa Ana, California, United States

Calfornia Neurosc Resrch Med; 🇺🇸 Sherman Oaks, California, United States

Southern California Research LLC; 🇺🇸 Simi Valley, California, United States

Mountain Neurological Research Center, Inc.; 🇺🇸 Basalt, Colorado, United States

Denver Neurological Research; 🇺🇸 Denver, Colorado, United States

Mile High Research Center; 🇺🇸 Denver, Colorado, United States

JEM Research Institute; 🇺🇸 Atlantis, Florida, United States

Visionary Investigators Network; 🇺🇸 Aventura, Florida, United States

Brain Matters Research; 🇺🇸 Delray Beach, Florida, United States

Integrity Clinical Research, LLC; 🇺🇸 Doral, Florida, United States

Neuropsychiatric Research Cent; 🇺🇸 Fort Myers, Florida, United States

Finlay Medical Research Group; 🇺🇸 Greenacres City, Florida, United States

Indago Research & Health Center Inc.; 🇺🇸 Hialeah, Florida, United States

Hlth Cr Family Rehab & Res Ctr; 🇺🇸 Miami, Florida, United States

K2 The Villages; 🇺🇸 Lady Lake, Florida, United States

K2 Medical Research, Maitland; 🇺🇸 Maitland, Florida, United States

AZ Groeninge - Kortrijk - Neurologie; 🇧🇪 Kortrijk, Belgium

Premier Clin Res Inst, Inc.; 🇺🇸 Miami, Florida, United States

Premier Clinical Research Institute, Inc.; 🇺🇸 Miami, Florida, United States

Novel Clinical Research Center, LLC; 🇺🇸 Miami, Florida, United States

IMIC, Inc- Medical Research; 🇺🇸 Miami, Florida, United States

The Neurology Research Group; 🇺🇸 Miami, Florida, United States

Visionary Inv Ntwrk_Miami; 🇺🇸 Miami, Florida, United States

Aqualane Clinical Research; 🇺🇸 Naples, Florida, United States

Suncoast Clin Res Port Richey; 🇺🇸 New Port Richey, Florida, United States

Suncoast Clinical Research, Inc._New Port Richey; 🇺🇸 New Port Richey, Florida, United States

Combined Research Orlando Phase I-IV; 🇺🇸 Orlando, Florida, United States

Advanced Research Consultants, Inc.; 🇺🇸 Palm Beach Gardens, Florida, United States

Intercoastal Medical Group; 🇺🇸 Sarasota, Florida, United States

The Roskamp Institute, Inc.; 🇺🇸 Sarasota, Florida, United States

Axiom Clinical Research of Florida; 🇺🇸 Tampa, Florida, United States

Stedman Clinical Trials LLC; 🇺🇸 Tampa, Florida, United States

Palm Beach Neuro Premiere Res; 🇺🇸 West Palm Beach, Florida, United States

Conquest Research; 🇺🇸 Winter Park, Florida, United States

Center for Adv Res & Education; 🇺🇸 Gainesville, Georgia, United States

Hawaii Neuroscience, Memory Disorders Center; 🇺🇸 Honolulu, Hawaii, United States

Velocity Clinical Research, Meridian; 🇺🇸 Meridian, Idaho, United States

Velocity Clinical Research; 🇺🇸 Meridian, Idaho, United States

Cotton-O'Neil Clinical Research Center; 🇺🇸 Topeka, Kansas, United States

University of Kentucky_Lexington_0; 🇺🇸 Lexington, Kentucky, United States

Northern Light Eastern Maine Medical Center; 🇺🇸 Bangor, Maine, United States

HealthPartners Center for Memory and Aging; 🇺🇸 Saint Paul, Minnesota, United States

Hattiesburg Clinic; 🇺🇸 Hattiesburg, Mississippi, United States

Patient First MD,clinical Trials; 🇺🇸 Middletown, New Jersey, United States

Advanced Memory Research Institute of NJ; 🇺🇸 Toms River, New Jersey, United States

Neurological Assoc Long Island; 🇺🇸 Lake Success, New York, United States

Richmond Behavioral Associates; 🇺🇸 Staten Island, New York, United States

New Hope Clinical Research; 🇺🇸 Charlotte, North Carolina, United States

AMC Research, LLC; 🇺🇸 Matthews, North Carolina, United States

Insight Clinical Trials LLC; 🇺🇸 Beachwood, Ohio, United States

Central States Research, LLC; 🇺🇸 Tulsa, Oklahoma, United States

Summit Research Network Oregon Inc.; 🇺🇸 Portland, Oregon, United States

The Clinical Trial Center; 🇺🇸 Jenkintown, Pennsylvania, United States

Coastal Neurology; 🇺🇸 Port Royal, South Carolina, United States

Genesis Neuroscience Clinic; 🇺🇸 Knoxville, Tennessee, United States

Vanderbilt Medical Center; 🇺🇸 Nashville, Tennessee, United States

Univ Of Texas Hlth Science Cntr; 🇺🇸 Houston, Texas, United States

Glenn Biggs Inst-Alzhm Neuro; 🇺🇸 San Antonio, Texas, United States

Shirzadi Shahin, MD; 🇺🇸 Sugar Land, Texas, United States

Integrated Neurology Services; 🇺🇸 Falls Church, Virginia, United States

Instituto Medico Especializado_Capital Federal; 🇦🇷 Ciudad de Buenos Aires, Buenos Aires, Argentina

Instituto de Investigaciones Metabolicas (IDIM); 🇦🇷 Buenos Aires, Argentina

Hospital Italiano; 🇦🇷 Buenos Aires, Argentina

Clínica Nuestra Señora de las Nieves; 🇦🇷 Caba, Argentina

St Vincent's Hospital; 🇦🇺 Darlinghurst, New South Wales, Australia

Southern Neurology; 🇦🇺 Kogarah, New South Wales, Australia

Hunter New England Local Health District - Neuropsychiatry; 🇦🇺 Waratah, New South Wales, Australia

The Prince Charles Hospital; 🇦🇺 Chermside, Queensland, Australia

Medical and Cognitive Research Unit - Austin Health; 🇦🇺 Ivanhoe, Victoria, Australia

LKH-Univ. Kliniken Innsbruck; 🇦🇹 Innsbruck, Austria

Medizinische Univ. Innsbruck; 🇦🇹 Innsbruck, Austria

L2 IP Instituto de Pesquisas Clinicas Ltda; 🇧🇷 Brasília, Distrito Federal, Brazil

Instituto de Neurologia de Curitiba; 🇧🇷 Curitiba, Parana, Brazil

Clinica Clinilive Ltda; 🇧🇷 Maringa, Parana, Brazil

Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda.; 🇧🇷 Porto Alegre, Rio Grande Do Sul, Brazil

CPQuali Pesquisa Clínica Ltda; 🇧🇷 São Paulo, Sao Paulo, Brazil

BR Trials - Ensaios Clínicos e Consultoria Ltda.; 🇧🇷 São Paulo, Sao Paulo, Brazil

Assoc. Paulista para o Desenvolvimento da Medicina - UNIFESP; 🇧🇷 São Paulo, Sao Paulo, Brazil

Centro de Psiquiatria Sandra Rushel; 🇧🇷 Rio de Janeiro, Brazil

"MHATNP "Sv. Naum"" EAD; 🇧🇬 Sofia, Bulgaria

DCC Sv. Vrach and Sv. Sv. Kuzma and Damyan; 🇧🇬 Sofia, Bulgaria

"UMHAT "Aleksandrovska", Neurology clinic; 🇧🇬 Sofia, Bulgaria

MMA, MHAT-Sofia, Neurology clinic; 🇧🇬 Sofia, Bulgaria

OCT Research ULC (dba Okanagan Clinical Trials); 🇨🇦 Kelowna, British Columbia, Canada

Medical Arts Health Research Group_Kelowna; 🇨🇦 Penticton, British Columbia, Canada

Island Health (Research and Capacity Building); 🇨🇦 Victoria, British Columbia, Canada

True North Clinical Research - Halifax; 🇨🇦 Halifax, Nova Scotia, Canada

True North Clinical Research - New Minas; 🇨🇦 New Minas, Nova Scotia, Canada

Ottawa Memory Clinic; 🇨🇦 Ottawa, Ontario, Canada

Douglas Hosp Res Ctr; 🇨🇦 Montréal, Quebec, Canada

CHU de Quebec-Universite Laval; 🇨🇦 Québec, Quebec, Canada

Neuro Health Centrum s.r.o.; 🇨🇿 Brno-Lisen, Czechia

AGE Centrum; 🇨🇿 Olomouc, Czechia

AD71 s.r.o.; 🇨🇿 Praha 10, Czechia

Neuropsychiatrie; 🇨🇿 Praha 6 Dejvice, Czechia

Vestra Clinics s.r.o.; 🇨🇿 Rychnov nad Kneznou, Czechia

Aarhus Universitetshospital; 🇩🇰 Aarhus N, Denmark

Centre Hospitalier Universitaire de Bordeaux-Hopital Pellegrin; 🇫🇷 Bordeaux, France

Hospices Civils de Lyon-Hopital Pierre Wertheimer; 🇫🇷 Bron, France

Centre Hospitalier Universitaire de Dijon-Hopital Le Bocage; 🇫🇷 Dijon, France

Assistance Publique Hopitaux de Marseille-Hopital de La Timone-1; 🇫🇷 Marseille, France

Centre Hospitalier Universitaire de Nice-Institut Claude Pompidou; 🇫🇷 Nice, France

Aphp-Hopital Lariboisiere-1; 🇫🇷 Paris, France

Aphp-Hopital La Pitie Salpetriere-3; 🇫🇷 Paris, France

Centre Hospitalier Universitaire Reims-Hopital Maison Blanche; 🇫🇷 Reims cedex, France

Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec-2; 🇫🇷 Saint Herblain, France

Les Hopitaux Universitaires de Strasbourg-Hopital de La Robertsau; 🇫🇷 Strasbourg, France

Centre Hospitalier Universitaire de Toulouse-Hopital La Grave; 🇫🇷 Toulouse, France

Hospices Civils de Lyon-Hopital Des Charpennes; 🇫🇷 Villeurbanne, France

Zentrum für klinische Forschung Dr. med. Irma Schöll GmbH; 🇩🇪 Bad Homburg, Hessen, Germany

Universitätsklinikum RWTH Aachen, Neurologie; 🇩🇪 Aachen, Germany

Studienzentrum Dr. Bischof GmbH; 🇩🇪 Böblingen, Germany

Neuro Centrum Science GmbH; 🇩🇪 Erbach, Germany

Universitätsklinikum Hamburg-Eppendorf, Psychiatrie; 🇩🇪 Hamburg, Germany

Universitätsklinikum Köln - Klinik und Poliklinik für Psychiatrie und Psychotherapie; 🇩🇪 Köln, Germany

Universitätsmedizin Mainz, Psychiatrie; 🇩🇪 Mainz, Germany

Zentralinstitut für Seelische Gesundheit - Psychiatrie und Psychotherapie; 🇩🇪 Mannheim, Germany

LMU Klinikum - Institut für Schlaganfall- und Demenzforschung (ISD); 🇩🇪 München, Germany

Universitätsklinikum Ulm, Neurologie; 🇩🇪 Ulm, Germany

Studienzentrum Nord-West; 🇩🇪 Westerstede, Germany

Henry Dunant Hospital Center,2nd Neurological Department; 🇬🇷 Athens, Greece

Aiginitio Hospital, 1st Neurology Clinic; 🇬🇷 Athens, Greece

"Hygeia" General Hospital of Athens, Memory clinic; 🇬🇷 Athens, Greece

Naval Hospital of Athens; 🇬🇷 Athens, Greece

DE Kenézy Gyula Campus, Pszichiátriai és Pszichoterápiai Klinika; 🇭🇺 Debrecen, Hungary

DE Gyógyszerfejlesztési Koordinációs Központ Pszichiátria; 🇭🇺 Debrecen, Hungary

Petz Aladar Megyei Korhaz; 🇭🇺 Gyor, Hungary

Keio University Hospital; 🇯🇵 Shinjuku-ku, Tokyo, Japan

Shizuoka City Shimizu Hospital_Neurology; 🇯🇵 Shizuoka-shi, Shizuoka, Japan

Kagawa Prefectural Central Hospital_Takamatsu-shi, Kagawa; 🇯🇵 Takamatsu-shi, Kagawa, Japan

Juntendo Tokyo Koto Geriatric Medical Center; 🇯🇵 Tokyo, Japan

Kurumi CLINIC; 🇯🇵 Tokyo, Japan

Tokyo Medical Univ. Hospital; 🇯🇵 Tokyo, Japan

Memory Clinic Toride; 🇯🇵 Toride-shi, Ibaraki, Japan

MI Clinic; 🇯🇵 Toyonaka-shi, Osaka, Japan

Medical Corporation Midorikai Wako Hospital; 🇯🇵 Wako-shi, Saitama, Japan

Dong-A University Medical Center; 🇰🇷 Busan, Korea, Republic of

Chungnam National University Hospital; 🇰🇷 Daejeon, Korea, Republic of

Chonnam National University Hospital; 🇰🇷 Gwangju, Korea, Republic of

Seoul National University Bundang Hospital; 🇰🇷 Gyeonggi-do, Korea, Republic of

Gachon University Gil Medical Center; 🇰🇷 Incheon, Korea, Republic of

Inha University Hospital; 🇰🇷 Incheon, Korea, Republic of

Hanyang University Medical Center; 🇰🇷 Seoul, Korea, Republic of

Hanyang university seoul hospital; 🇰🇷 Seoul, Korea, Republic of

Konkuk University Medical Center; 🇰🇷 Seoul, Korea, Republic of

Asan Medical Center; 🇰🇷 Seoul, Korea, Republic of

Samsung Medical Center_Seoul; 🇰🇷 Seoul, Korea, Republic of

Ewha Womans University Seoul Hospital; 🇰🇷 Seoul, Korea, Republic of

Hospital Universitario "Dr. Gonzalo Valdes Valdes"; 🇲🇽 Saltillo, Coahuila, Mexico

Hospital Universitario Dr. José Eleuterio González_Monterrey; 🇲🇽 Monterrey, Nuevo León, Mexico

Centro de Estudios Clínicos y Especialidades Médicas S.C.; 🇲🇽 Monterrey, Nuevo León, Mexico

Avix Investigación Clínica, S.C.; 🇲🇽 Monterrey, Nuevo León, Mexico

Hospital Angeles de Culiacan; 🇲🇽 Culiacan, Sinaloa, Mexico

Amphia Ziekenhuis; 🇳🇱 Breda, Netherlands

Brain Research Center; 🇳🇱 Den Bosch, Netherlands

Radboudumc; 🇳🇱 Nijmegen, Netherlands

Akershus universitetssykehus - Hukommelsesklinikken; 🇳🇴 Lørenskog, Norway

Linden sp. z o.o. sp. k.; 🇵🇱 Kraków, Małopolskie, Poland

Unidade Local De Saude De Lisboa Ocidental E.P.E. - Hospital Egas Moniz; 🇵🇹 Lisboa, Portugal

Hospital Beatriz Ângelo; 🇵🇹 Loures, Portugal

Unidade Local de Saúde de Santo António, E.P.E; 🇵🇹 Porto, Portugal

Campus Neurologico Senior; 🇵🇹 Torres Vedras, Portugal

Sana Monitoring SRL; 🇷🇴 Bucharest, Romania

Spitalul Clinic Cai Ferate Constanta; 🇷🇴 Constanta, Romania

Spitalul Clinic Judetean De Urgenta Sfantul Apostol Andrei Constanta; 🇷🇴 Constanta, Romania

Aria Clinic SRL; 🇷🇴 Sibiu, Romania

Joint Stock Company "Medical technologies"; 🇷🇺 Ekaterinburg, Russian Federation

Federal Siberian Research Clinical Center under FMBA of Rus; 🇷🇺 Krasnoyarsk, Russian Federation

FSAEI 1st Moscow Federal Med University na Sechenov; 🇷🇺 Moscow, Russian Federation

RMAPE; 🇷🇺 Moscow, Russian Federation

Pirogov Russian National Research Medical University MoH; 🇷🇺 Moscow, Russian Federation

Ezramed Clinic Llc; 🇷🇺 Omsk, Russian Federation

Research Center for Treatment and Rehabilitation "Phoenix"; 🇷🇺 Rostov-on-Don, Russian Federation

Psychiatric hospital of st. Nicholas the wonderworker; 🇷🇺 Saint Petersburg, Russian Federation

N.-E. State Medical University n.a. Mechnikov; 🇷🇺 Saint Petersburg, Russian Federation

S.M. Kirov Military Medical Academy,Depart.&Clinic Nerv Dis; 🇷🇺 Saint Petersburg, Russian Federation

Center of Clinica Trials "Nebbiolo"; 🇷🇺 Tomsk, Russian Federation

LLC "Clinic Stolet"; 🇷🇺 Tomsk, Russian Federation

National medical holdiNational medical holding "Medstandard"; 🇷🇺 Ufa, Russian Federation

Neurology clinic, University Clinical Center of Serbia; 🇷🇸 Belgrade, Serbia

Special Hospital for Psychiatric Disorders "Kovin"; 🇷🇸 Kovin, Serbia

University clinical center of Vojvodina, Neurology clinic; 🇷🇸 Novi Sad, Serbia

Psych. amb. CENTRUM ZDRAVIA R.B.K., s.r.o. Bardejov; 🇸🇰 Bardejov, Slovakia

I. neurologicka klinika LF UK a UNB; 🇸🇰 Bratislava, Slovakia

Psychiatricka klinika LF UK a UNB; 🇸🇰 Bratislava, Slovakia

Neurologicka klinika UPJS LF a UNLP; 🇸🇰 Kosice, Slovakia

Crystal Comfort s.r.o.; 🇸🇰 Vranov nad Toplou, Slovakia

UKC Ljubljana, Department of Neurology; 🇸🇮 Ljubljana, Slovenia

Excellentis Clinical Trial Consultants; 🇿🇦 George, Eastern Cape, South Africa

IATROS International; 🇿🇦 Bloemfontein, Free State, South Africa

Dr Stanley Lipschitz Clinic Inc; 🇿🇦 Johannesburg, Gauteng, South Africa

Denmar Psychiatric Hospital; 🇿🇦 Pretoria, Gauteng, South Africa

ACF Neurological service; 🇿🇦 Cape Town, Western Cape, South Africa

Flexivest Fourteen Research Centre; 🇿🇦 Cape Town, Western Cape, South Africa

Cape Trial Centre; 🇿🇦 Cape Town, Western Cape, South Africa

Hospital Santa Creu i Sant Pau; 🇪🇸 Barcelona, Spain

Fundación ACE; 🇪🇸 Barcelona, Spain

Fundación CITA; 🇪🇸 Donostia, Spain

Hospital Ramón y Cajal; 🇪🇸 Madrid, Spain

Hospital Quirón; 🇪🇸 Pozuelo de Alarcon, Spain

Hospital Universitari General de Catalunya; 🇪🇸 Sant Cugat del Vallès, Spain

Hospital Universitario Marqués de Valdecilla; 🇪🇸 Santander, Spain

Hospital Universitario Doctor Peset; 🇪🇸 Valencia, Spain

Minnesmottagning specialiserad Malmö; 🇸🇪 Malmö, Sweden

Karolinska Universitetssjukhuset, Huddinge; 🇸🇪 Stockholm, Sweden

Geriatriskt centrum, Umeå; 🇸🇪 Umeå, Sweden

Spitalzentrum Biel; 🇨🇭 Biel-Bienne, Switzerland

Centre de la Mémoire; 🇨🇭 Genève, Switzerland

Centre Leenaards de la mémoire CHUV; 🇨🇭 Lausanne, Switzerland

Klinik für Neurologie Kantonsspital St.Gallen; 🇨🇭 St. Gallen, Switzerland

Hacettepe University Medical Faculty Hospital; 🇹🇷 Altindag/Ankara, Turkey

Eskisehir Osmangazi University Sağlık Uygulama ve Arastirma; 🇹🇷 Eskisehir, Turkey

Istanbul University Medical Faculty Neurology Department; 🇹🇷 Istanbul, Turkey

Izmir Economics University Medical Point Hospital Neurology D; 🇹🇷 Izmir, Turkey

Ondokuz Mayis University Saglik Uygulama ve Arastirma Merkez; 🇹🇷 Samsun, Turkey

Chebotarev State Institute of Gerontology of the NAMS of Ukr; 🇺🇦 Kyiv, Ukraine

Fritchie Centre; 🇬🇧 Cheltenham, Gloucestershire, United Kingdom

Royal Cornhill Hospital; 🇬🇧 Aberdeen, United Kingdom

RICE - The Research Institute for the Care of Older People; 🇬🇧 Bath, United Kingdom

Dementia Research Unit,; 🇬🇧 Crowborough, United Kingdom

Dementia Research Unit; 🇬🇧 Crowborough, United Kingdom

Ninewells Hospital; 🇬🇧 Dundee, United Kingdom

Western General Hospital; 🇬🇧 Edinburgh, United Kingdom

St Pancras Clinical Research; 🇬🇧 London, United Kingdom

St George's Hospital; 🇬🇧 London, United Kingdom

Imperial College London - Imperial College Memory Research Centre; 🇬🇧 London, United Kingdom

Greater Manchester Mental Health NHS Foundation Trust; 🇬🇧 Manchester, United Kingdom

NeuroClin; 🇬🇧 Motherwell, United Kingdom

Newcastle University; 🇬🇧 Newcastle Upon Tyne, United Kingdom

Warneford Hospital; 🇬🇧 Oxford, United Kingdom

Moorgreen Hospital; 🇬🇧 Southampton, United Kingdom

Kings Hill Research Centre; 🇬🇧 Swindon, United Kingdom